Nuveen Asset Management LLC Has $1.49 Million Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Nuveen Asset Management LLC cut its position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 25.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 294,392 shares of the company's stock after selling 100,748 shares during the period. Nuveen Asset Management LLC owned about 0.23% of Humacyte worth $1,487,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of HUMA. Vontobel Holding Ltd. acquired a new position in Humacyte in the fourth quarter worth $50,000. Petros Family Wealth LLC bought a new stake in shares of Humacyte in the fourth quarter worth about $50,000. Syon Capital LLC bought a new stake in shares of Humacyte in the fourth quarter worth about $54,000. Ameriprise Financial Inc. bought a new stake in shares of Humacyte in the fourth quarter worth about $58,000. Finally, Hsbc Holdings PLC bought a new position in shares of Humacyte during the fourth quarter worth about $62,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte Trading Down 0.4%

Shares of NASDAQ:HUMA traded down $0.01 during trading on Thursday, hitting $2.62. 4,152,453 shares of the company were exchanged, compared to its average volume of 3,787,846. The stock has a market cap of $406.41 million, a price-to-earnings ratio of -1.96 and a beta of 2.00. Humacyte, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $9.79. The firm has a fifty day moving average price of $1.75 and a two-hundred day moving average price of $3.25.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. As a group, research analysts predict that Humacyte, Inc. will post -1.27 EPS for the current year.

Insider Buying and Selling

In other Humacyte news, CFO Dale A. Sander bought 20,000 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The shares were acquired at an average cost of $1.53 per share, with a total value of $30,600.00. Following the acquisition, the chief financial officer now owns 40,600 shares of the company's stock, valued at $62,118. The trade was a 97.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kathleen Sebelius bought 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The shares were acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 83,993 shares of company stock valued at $118,224. 5.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

HUMA has been the topic of several research reports. Benchmark cut their target price on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. D. Boral Capital restated a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research note on Tuesday, May 13th. HC Wainwright initiated coverage on Humacyte in a research note on Wednesday, May 14th. They issued a "buy" rating and a $4.00 target price on the stock. Finally, Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.